Tandem Diabetes Care INC 8-K filings

Tandem Diabetes Care's stockholders approved key amendments to its charter and its long-term incentive plan at the 2026 Annual Meeting.

Tandem Diabetes Care announced the termination of its Chief Commercial Officer, Mark Novara, effective May 18, 2026, stating the company's strategy remains unchanged.

Tandem Diabetes Care reported record first quarter pump shipments and sales, with revenue reaching $247.2 million and gross margin improving to 55%.

Tandem Diabetes Care, Inc. completed a private offering of $300.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032, including the full exercise of the initial purchasers' option.

Tandem Diabetes Care reported record Q4 2025 sales and surpassed $1 billion in full-year worldwide sales, while providing 2026 financial guidance.

Tandem Diabetes Care, Inc. adopted amended and restated bylaws, updating corporate governance provisions related to shareholder nominations, meeting procedures, and indemnification.

Tandem Diabetes Care, Inc. announced the appointment of Sandra Beaver, a seasoned finance executive, to its Board of Directors, effective November 7, 2025.

Tandem Diabetes Care announced record third quarter 2025 sales and reaffirmed its full year 2025 financial guidance, despite a decrease in Adjusted EBITDA.

Tandem Diabetes Care, Inc. announced FDA 510(k) clearance for its SteadiSet infusion set, designed for up to seven days of continuous insulin delivery.

Tandem Diabetes Care announced record second quarter sales and provided updated full-year 2025 financial guidance, including a revised Adjusted EBITDA margin forecast.

Tandem Diabetes Care, Inc. announced a comprehensive settlement with Roche to resolve all patent disputes related to its t:slim X2 pump, involving a $36 million payment and mutual cross-licensing, while also reporting the successful outcomes of its annual stockholders' meeting.

Tandem Diabetes Care announces CE mark approval for its Tandem Mobi insulin delivery system with Control-IQ+ technology, paving the way for EU commercial launches by the end of 2025.

Tandem Diabetes Care's subsidiary, Capillary Biomedical, receives FDA clearance for its SteadiSet infusion set, designed for three-day use in adult patients with Type 1 diabetes.

Tandem Diabetes Care announced record first quarter sales with worldwide growth of 22% and reaffirmed its 2025 financial guidance.

Tandem Diabetes Care announces record sales for Q4 and full year 2024, driven by strong growth in pump shipments and expansion in the U.S. market, while also providing financial guidance for 2025.

Tandem Diabetes Care announced record third-quarter sales, driven by a 31% increase in worldwide GAAP sales, and raised its full-year 2024 sales guidance.

Tandem Diabetes Care announced a 13% increase in worldwide GAAP sales for the second quarter of 2024 and raised its full-year sales guidance.

Tandem Diabetes Care has appointed Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024.

Tandem Diabetes Care and Dexcom have extended their collaboration by entering into amended development and commercialization agreements, focusing on integrating Tandem's Sigi insulin pump with Dexcom's G7 CGM device.

Tandem Diabetes Care's stockholders elected nine directors and approved amendments to the company's stock purchase and long-term incentive plans at their annual meeting on May 22, 2024.

Tandem Diabetes Care has extended its manufacturing agreement with Unomedical and received Health Canada approval for Trurapi U-100 insulin compatibility with its t:slim X2 pump.

Tandem Diabetes Care announced a 13% increase in worldwide GAAP sales for the first quarter of 2024 and updated its full-year sales guidance.

Tandem Diabetes Care has secured FDA clearance for its Tandem Mobi insulin pump, expanding its use to include children aged two years and older.

Tandem Diabetes Care successfully closed a private offering of $316.25 million in convertible senior notes due 2029, utilizing proceeds for debt repurchase and share buybacks.

Tandem Diabetes Care announced its fourth quarter and full year 2023 financial results, highlighting the launch of new products and providing financial guidance for 2024.